Clinical outcomes and survival differences between primary, secondary and concomitants carcinoma <i>in situ</i> of urinary bladder treated with BCG immunotherapy.

Piszczek, Radoslaw; Krajewski, Wojciech; Malkiewicz, Bartosz; Krajewski, Piotr; Tukiendorf, Andrzej; Zdrojowy, Romuald; Kolodziej, Anna

Clinical outcomes and survival differences between primary, secondary and concomitants carcinoma in situ of urinary bladder treated with BCG immunotherapy.

Piszczek, Radoslaw; Krajewski, Wojciech; Malkiewicz, Bartosz; Krajewski, Piotr; Tukiendorf, Andrzej; Zdrojowy, Romuald; Kolodziej, Anna.

Afiliação

Piszczek R; Department of Urology and Oncologic Urology, Lowersilesian Specialistic Hospital, Wroclaw, Poland.
Krajewski W; Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland.
Malkiewicz B; Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland.
Krajewski P; Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland.
Tukiendorf A; Department of Public Health, Wroclaw Medical University, Wroclaw, Poland.
Zdrojowy R; Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland.
Kolodziej A; Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland.

Transl Androl Urol ; 9(3): 1338-1344, 2020 Jun.

Article em En | MEDLINE | ID: mdl-32676418

Palavras-chave

Bladder cancer (BC); carcinoma in situ (CIS); progression; recurrence

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Transl Androl Urol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Polônia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google